PRL3通过抑制T细胞信号通路和凋亡增强T细胞急性淋巴细胞白血病生长
该研究在T细胞急性淋巴细胞白血病(T-ALL)中鉴定出蛋白酪氨酸磷酸酶4A3型(PRL3)作为协同致癌驱动因子。PRL3在部分原代人T-ALL中表达,常与MYC共扩增,并与MYC协同在转基因斑马鱼中引发早发性ALL,且为人T-ALL生长和维持所必需。机制上PRL3抑制包括VAV1调控的下游T细胞磷酸化信号通路,进而抑制白血病细胞凋亡,作者提示靶向PRL3磷酸酶可能是有用的T-ALL治疗策略。
要点
- PRL3在部分原代人T-ALL中表达,并常与MYC共扩增。
- PRL3与MYC协同在转基因斑马鱼中引发早发性ALL,且为人T-ALL生长和维持所必需。
- PRL3抑制VAV1等下游T细胞磷酸化信号通路并抑制白血病细胞凋亡。
核心结论
- PRL3是入T-ALL的协同致癌驱动因子,作者提示靶向PRL3磷酸酶可能是有用的T-ALL治疗策略。
研究设计与样本
- 研究采用原代人T-ALL样本、转基因斑马鱼模型及质谱磷酸化蛋白质组学分析,具体样本量原文未报告。
主要发现
- PRL3在部分原代人T-ALL中表达,并常与MYC共扩增。
- PRL3与MYC协同在转基因斑马鱼中引发早发性ALL,且为人T-ALL生长和维持所必需。
- 质谱磷酸化蛋白质组学及机制研究显示PRL3抑制包括VAV1调控通路在内的下游T细胞磷酸化信号通路,进而抑制白血病细胞凋亡。
临床怎么用
- 作者认为靶向PRL3磷酸酶可能是有用的T-ALL治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-ALL. PRL3 is expressed in a large fraction of primary human T-ALLs and is commonly co-amplified with MYC. PRL3 also synergized with MYC to initiate early-onset ALL in transgenic zebrafish and was required for human T-ALL growth and maintenance. Mass-spectrometry phosphoproteomic analysis and mechanistic studies uncovered that PRL3 suppresses downstream T-cell phosphorylation signaling pathways, including those modulated by VAV1, and subsequently suppresses apoptosis in leukemia cells. Taken together, our studies have identified new roles for PRL3 as a collaborating oncogenic driver in human T-ALL and suggest that therapeutic targeting of the PRL3 phosphatase will likely be a useful treatment strategy for T-ALL.
引用
- Garcia EG, Veloso A, Oliveira ML, et al. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. Leukemia. 2020. PMID: 32606318. doi:10.1038/s41375-020-0937-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。